In conclusion, future directions for CTLA-4-based breast cancer immunotherapy include combination therapy and individualized treatment, and the complex mechanisms governing CTLA-4 immunotherapy will continue to be explored. This evidence concerns the gene CTLA4 and breast carcinoma.